Tetratherix Says Safety Review for Second Patient Group in Surgical Scar Prevention Product Trial Showed No Adverse Events; Shares Jump 5%

MT Newswires Live

01/13

Tetratherix (ASX:TTX) said the second safety review of the second patient group in the clinical trial of its TetraDerm product for the potential prevention of scar formation in surgical incisions was completed without any procedural or technical adverse events, according to a Tuesday Australian bourse filing.

Nine patients in the second group of the trial successfully completed their six-week follow up assessments, per the filing. Patient recruitment for the third group of the trial has started.

The company's shares jumped nearly 5% in recent trading on Tuesday.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2603575803"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603575803\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603575803?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-13 10:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603575803","market":"nz","top_or_hot":-1,"title":"Tetratherix Says Safety Review for Second Patient Group in Surgical Scar Prevention Product Trial Showed No Adverse Events; Shares Jump 5%","media":"MT Newswires Live","content":"<html><body><p> Tetratherix (ASX:TTX) said the second safety review of the second patient group in the clinical trial of its TetraDerm product for the potential prevention of scar formation in surgical incisions was completed without any procedural or technical adverse events, according to a Tuesday Australian bourse filing.</p><p>Nine patients in the second group of the trial successfully completed their six-week follow up assessments, per the filing. Patient recruitment for the third group of the trial has started.</p><p>The company's shares jumped nearly 5% in recent trading on Tuesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tetratherix Says Safety Review for Second Patient Group in Surgical Scar Prevention Product Trial Showed No Adverse Events; Shares Jump 5%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTetratherix Says Safety Review for Second Patient Group in Surgical Scar Prevention Product Trial Showed No Adverse Events; Shares Jump 5%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-01-13 10:12</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Tetratherix (ASX:TTX) said the second safety review of the second patient group in the clinical trial of its TetraDerm product for the potential prevention of scar formation in surgical incisions was completed without any procedural or technical adverse events, according to a Tuesday Australian bourse filing.</p><p>Nine patients in the second group of the trial successfully completed their six-week follow up assessments, per the filing. Patient recruitment for the third group of the trial has started.</p><p>The company's shares jumped nearly 5% in recent trading on Tuesday.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TTX.AU","symbol_name":"Tetratherix Ltd","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2603575803","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603575803","pubTimestamp":1768270339,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Tetratherix  said the second safety review of the second patient group in the clinical trial of its TetraDerm product for the potential prevention of scar formation in surgical incisions was completed without any procedural or technical adverse events, according to a Tuesday Australian bourse filing.Nine patients in the second group of the trial successfully completed their six-week follow up assessments, per the filing. Patient recruitment for the third group of the trial has started.The company's shares jumped nearly 5% in recent trading on Tuesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TTX.AU":"Tetratherix Ltd","BK7067":"生物科技"},"translate_title":"Tetratherix表示，手术疤痕预防产品试验中第二组患者的安全性审查显示没有不良事件；股价上涨5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TTX.AU":1},"content_text":"Tetratherix (ASX:TTX) said the second safety review of the second patient group in the clinical trial of its TetraDerm product for the potential prevention of scar formation in surgical incisions was completed without any procedural or technical adverse events, according to a Tuesday Australian bourse filing.Nine patients in the second group of the trial successfully completed their six-week follow up assessments, per the filing. Patient recruitment for the third group of the trial has started.The company's shares jumped nearly 5% in recent trading on Tuesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}